People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Other Health Care, Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Code Biotherapeutics, Inc. | — | Other Health Care | Series B | $47.5M | $465.5M | 2022 |
| Ray Therapeutics, Inc. | — | Biotechnology | Series A | $20.0M | $126.7M | 2021 |
| NV Therapeutics, Inc. | — | Pharma | Seed | $3.0M | $12.8M | 2024 |
Dmitry Kuzmin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dmitry Kuzmin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Edward Mathers | 1 | 12 |
| Tiba Aynechi | 1 | 9 |
| Sean Ainsworth | 1 | 5 |
| Andrew Howard | 1 | 4 |
| Russ Fein | 1 | 4 |
| Raymond Camahort | 1 | 4 |
| Joseph Truitt | 1 | 2 |
| Robert Lin | 1 | 2 |
| Gary Abrams | 1 | 2 |
| Paul Bresge | 1 | 2 |
| Hannah Chang | 1 | 2 |
| Victor Stone | 1 | 2 |
| Edward C. Mathers | 1 | 1 |
| Robert C. Lin | 1 | 1 |
| Audrey Kozlov | 1 | 1 |
| Daniel Dever | 1 | 1 |
| Kevin Holden | 1 | 1 |
| Cameron Gallagher | 1 | 1 |
| Brian McVeigh | 1 | 1 |
| Kathy Rouan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.